← 返回

基于免疫治疗的联合方案后中期[(18)F]FDG PET/CT 在鼻型结外 NK/T 细胞淋巴瘤中的预后价值

英文原题:Prognostic value of interim [(18)F]FDG PET/CT after immunotherapy-based combinations in extranodal NK/T-cell lymphoma, nasal type.

查看英文原题

Prognostic value of interim [(18)F]FDG PET/CT after immunotherapy-based combinations in extranodal NK/T-cell lymphoma, nasal type.

PubMed 2025/01/21(内容时间) Eur Radiol Q1 · IF 6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

免疫治疗为基础的全身治疗后的中期 PET/CT 对 ENKTL 显示出独立预后价值。将中期 PET/CT 与 PINK-E 联合的模型可能是一种有效的预后工具。问题 中期[18F]FDG PET/CT 在结外自然杀伤/T 细胞淋巴瘤中的预后价值仍不确定,尤其是在引入免疫治疗之后。发现 免疫治疗为基础的全身治疗后中期[18F]FDG PET/CT 上的 Deauville 5 分法是新诊断结外自然杀伤/T 细胞淋巴瘤的独立预测因素。临床意义 在免疫治疗时代,中期[18F]FDG PET/CT 单独或联合 NK 细胞淋巴瘤-Epstein-Barr 病毒预后指数(PINK-E)模型是一种有效且更优的临床应用预后工具。

研究思路结论见上方概要

评估结外NK/T细胞淋巴瘤(ENKTL)患者在接受以免疫治疗为基础的系统治疗后,中期[18F]氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描([18F]FDG PET/CT)的预后价值。

我们回顾性纳入133例新诊断鼻型ENKTL患者,这些患者在2-4个周期免疫治疗为基础的治疗后接受了中期[ 18 F]FDG PET/CT扫描。中期PET/CT通过最大标准化摄取值(SUV max)、Deauville 5分法(DS)和早期治疗反应进行判读。通过Kaplan-Meier分析生成生存曲线,并使用log-rank检验进行比较,评估总生存期(OS)和无进展生存期(PFS)的预后价值。进行单因素和多因素Cox比例风险分析,以评估对生存的独立影响。模型性能通过时间依赖性曲线下面积(time-AUC)、一致性指数(C-index)和赤池信息量准则(AIC)进行评估。

SUV max 高(> 9.2)、DS 5,或 interim PET/CT 显示疾病稳定(SD)或复发/进展(PD)的患者,Kaplan-Meier 估计分别显示 OS 和 PFS 显著不利。单因素和多因素分析后,interim PET/CT 参数仍是 OS 和 PFS 的独立预测因素。我们将 interim DS 与NK 细胞淋巴瘤预后指数-Epstein-Barr 病毒(PINK-E)模型结合,将我们的队列分为 3 个风险类别:低风险(0-2 个风险因素)、中等风险(3 个风险因素)和高风险(≥ 4 个风险因素),其对 OS 和 PFS 的分层显著且优于 PINK-E。

展开英文摘要原文

To evaluate the prognostic value of interim [ 18 F]Fluorodeoxyglucose positron emission tomography/computed tomography ([ 18 F]FDG PET/CT) after immunotherapy-based systemic therapies in extranodal natural killer/T-cell lymphoma (ENKTL).

We retrospectively recruited 133 newly diagnosed nasal-type ENKTL patients who underwent interim [ 18 F]FDG PET/CT scans after 2-4 cycles of immunotherapy-based treatments. Interim PET/CT was interpreted by maximum standardized uptake value (SUV max ), Deauville 5-point scale (DS), and early treatment response. The prognostic value of overall survival (OS) and progression-free survival (PFS) was assessed with survival curves generated using Kaplan-Meier analysis and compared using the log-rank test. Univariate and multivariate Cox proportional hazards analyses were performed to evaluate the independent effects for survival. Model performance was assessed with a time-dependent area under the curve (time-AUC), concordance index (C-index), and the Akaike information criterion (AIC).

Patients with high SUV max (> 9.2), DS 5, or with stable disease (SD) or relapsed/progressive disease (PD) on interim PET/CT showed significantly unfavorable OS and PFS with the Kaplan-Meier estimate, respectively. The interim PET/CT parameters remained independent predictors for both OS and PFS after univariate and multivariate analysis. We combined interim DS with the prognostic index for natural killer cell lymphoma-Epstein-Barr virus (PINK-E) model to stratify our cohort into 3 risk categories: low-risk (0-2 risk factors), intermediate-risk (3 risk factors), and high-risk (≥ 4 risk factors), which showed significant and superior stratifications of OS and PFS than PINK-E.

Interim PET/CT after immunotherapy-based systemic treatments showed independent prognostic value for ENKTL. The model combining interim PET/CT with PINK-E might be an effective prognostic tool. KEY POINTS: Question The prognostic value of interim [ 18 F]FDG PET/CT in extranodal natural killer/T-cell lymphoma remains uncertain, especially after the introduction of immunotherapy. Findings Deauville 5-point scale on interim [ 18 F]FDG PET/CT after immunotherapy-based systemic therapies was an independent predictor for newly diagnosed extranodal natural killer/T-cell lymphomas. Clinical relevance Interim [ 18 F]FDG PET/CT alone or combined with the prognostic index for natural killer cell lymphoma-Epstein-Barr virus (PINK-E) model is an effective and superior prognostic tool for clinical application in the era of immunotherapy.

论文信息

作者
Liu L、Hao S、Chen W、Jing M、Li S、Zhang W、Liang L、Fan W
第一作者单位
Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.China
通讯作者单位
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China. zhangyj@sysucc.org.cn.China
期刊
European radiology2025 Jul
原文标识
PubMed 39836202 · DOI 10.1007/s00330-024-11276-4